Environment Agency: Glaxosmithkline Environmental Permit Surrender SG1 2NY Approved

• The Environment Agency has issued a decision regarding environmental permits for Glaxosmithkline Research & Development Limited.
• This decision involves the surrender of permit EPR/YP3236SA/S008 and a variation to permit EPR/YP3236SA/V009 for the Stevenage Energy Centre at SG1 2NY.
• The permits fall under the stringent requirements of the Industrial Emissions Directive.
• The detailed 26-page decision document, published as a 528 KB PDF, outlines the regulatory actions.
• This Environment Agency permit decision provides a precedent for managing environmental obligations during site changes under IED.

This Environment Agency permit decision holds significant implications for other industrial operators, particularly those managing complex facilities under the Industrial Emissions Directive.

The Environment Agency has recently issued a significant decision concerning the environmental permits held by Glaxosmithkline Research & Development Limited. This regulatory action specifically addresses the Stevenage Energy Centre located in Gunnels Wood, identified by the postcode SG1 2NY. The decision involves both the surrender of one permit, referenced as EPR/YP3236SA/S008, and a variation to another, designated EPR/YP3236SA/V009.

The published decision document, which spans 26 pages and is available as a 528 KB PDF file, details the specifics of these changes. It outlines the conditions and rationale behind the Environment Agency's approval for the Glaxosmithkline environmental permit surrender SG1 2NY and the associated variation. Such decisions are routinely made public by the Environment Agency to ensure transparency in environmental regulation, particularly for facilities operating under stringent directives.

The regulatory actions taken regarding Glaxosmithkline's Stevenage Energy Centre permit fall under the purview of the Industrial Emissions Directive (IED). This directive establishes a comprehensive framework for controlling and reducing industrial emissions, which the UK has incorporated into its domestic environmental law. Facilities operating under the IED are subject to rigorous environmental standards and require specific permits, such as the Glaxosmithkline Research & Development environmental permit, to ensure compliance with emission limits and operational requirements.

The Environment Agency is the primary body responsible for implementing and enforcing the IED in England. This includes the crucial task of issuing, varying, and accepting the surrender of Industrial Emissions Directive permits. Their decisions, like the recent one concerning Glaxosmithkline, serve as critical precedents for how industrial operators must manage their environmental responsibilities, from initial operation through to decommissioning or significant operational changes. The detailed 26-page document provides insight into the agency's process for evaluating such requests, ensuring that environmental protection remains paramount even as site operations evolve.

This Environment Agency permit decision holds significant implications for other industrial operators, particularly those managing complex facilities under the Industrial Emissions Directive. The detailed process documented in the 26-page decision for the Glaxosmithkline environmental permit surrender SG1 2NY provides a clear example of the regulatory scrutiny applied to such actions. It underscores the necessity for meticulous planning and adherence to environmental standards when considering site decommissioning or substantial operational changes that necessitate permit variations or surrenders.

For legal professionals and compliance officers advising industrial clients, this specific case offers valuable insight into the Environment Agency's expectations and procedures. Reviewing the specifics of the EPR/YP3236SA/S008 surrender and the EPR/YP3236SA/V009 variation can inform strategies for future permit applications, modifications, or site closures. It reinforces the principle that even when operations cease or change significantly, the environmental obligations associated with an Industrial Emissions Directive permit remain a critical consideration, requiring formal regulatory approval and demonstrating continued commitment to environmental protection. This Glaxosmithkline Research & Development environmental permit decision serves as a practical guide to navigating these complex regulatory waters.

This Environment Agency decision details the surrender and variation of an environmental permit for Glaxosmithkline under the Industrial Emissions Directive. Lawyers and compliance officers advising industrial clients should review this document to understand the regulatory process and precedent for permit modifications or site decommissioning, particularly regarding IED compliance and the specific conditions applied to such actions.

Source: Original reporting via GOV.UK Environment Agency